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Abstract 
Hepatitis B infection remains a major cause of global mortality with Nigeria identified as a country with 
significant endemicity. Little is however known about the cost burden for managing Hepatitis B infection in this 
setting, or what policies exist to ensure access to care.  
A sample of one hundred patients recruited at National Assembly Medical Centre was screened for Hepatitis B. 
The study aimed at identifying clinical outcomes and economic burden of treating Hepatitis B with a treatment 
regimen of Pegylated Interferon alfa-2a (PEG-INFalfa-2a) and Emtricitabine + Tenoforvir (ET). Parameters 
evaluated include viral load (VL), sero-conversion and liver function test (LFT). Direct and indirect medical 
costs that were determined include laboratory investigations (HBsAg), VL, LFT, drugs and visits.  
The result showed a 7.2% prevalence of HBsAg. Initial monotherapy with PEG-INFalfa-2a resulted in sero-
conversion in 5 out of the 8 treated cases (62.5%) with a drop in VL to an undetected value (less than 20 
copies/ml).  In the rest (37.5%), VL rose to a range of 12000 - 35000 copies/ml and elevated liver enzyme 
[Alanine Transaminase (ALT)] increased to a range of 94-197 u/ml. Therapy switch to ET in treatment phase 2 
(non-responsive in phase 1) led to a decrease of VL to 2500-3000 copies/ml. Follow up therapy with PEG-
INFalfa-2a resulted in further decrease after 96 weeks.  Mono-therapy with PEG-INFalfa-2a cost N2,395,250 
($14,089.91) while PEG-INFalfa-2a + ET was N4,182,333 ($24,601.96).  
The treatment of Hepatitis B infection is of significant importance to both individual patients, and the national 
healthcare system, due to the considerable costs. Considering Hepatitis B infection as a Public Health 
Emergency will stimulate the relevant policies which can stem the looming epidemic.  
Keywords: Hepatitis B; Pegylated-interferon; Outcomes; Costs; Policy  
 
1. Background 
Healthcare provision in Nigeria has been associated with significant problems. Key healthcare indices suggest 
that healthcare delivery in the Nigerian setting is inadequate. For instance, life expectancy at birth is still very 
low for both sexes. The national maternal mortality ratio as well as the national infant mortality rate are also 
poor (WHO 2013). Furthermore, access to safe and good quality healthcare is lacking, even at a basic level 
(Hargreaves 2002).  
Additionally, the Nigerian healthcare system has faced considerable challenges because of the increase in its 
health expenditures. These expenditures may have originated directly from the cost of diagnosis and treatment of 
the disease or indirectly from loss of productivity and quality of life. Considering the limited resources for 
delivery of healthcare services, effective healthcare delivery is one of the general concerns of healthcare systems 
over the world (Bojuwoye 1997). As treatment costs are the major portion of health expenditure in many 
countries, recognizing and analyzing the direct treatment costs of diseases may provide health care managers 
with a better understanding of their financing issues and strategies (Akani 2005). 
Hepatitis B virus (HBV) is one of the most prevalent blood-borne viruses worldwide, with chronic HBV 
infection afflicting more than 2 billion people while some 350 million are chronic carriers, harboring the virus in 
their liver (Forbi et al. 2007). This virus is responsible for 80% of all cases of primary liver cancer, which is one 
of the leading causes of death in Asia and Africa (Ferlay et al. 2010).  
Major clinical consequences of HBV infection include liver failure, cirrhosis, and hepatocellular carcinoma 
(HCC). These complications lead to more than 1 million deaths each year and make HBV the 10th leading cause 
of death worldwide (Mahoney 1999; Lee 1997; WHO 1997; WHO 2000). HCC incidence has increased 
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worldwide, and the disease is now the 5th most frequent cancer, killing 300,000 – 500,000 people each year 
(Lavanchy 2004) Thus, HBV infection is an important public health problem, especially for developing countries 
where the endemicity is often significant.  
About two billion people are infected with HBV globally with over 620,000 deaths annually (Maiyaki 2014). 
The prevalence of HBV infection varies markedly in different geographic areas of the world, as well as in 
different population subgroups (Yu 2000; WHO 2000). Overall, approximately 45% of the global population live 
in areas of high chronic HBV prevalence (Lavanchy 2004). Nigeria has been classified as an HBV endemic zone, 
based on global HBV endemicity (Odemuyiwa et al. 2001; Forbi et al. 2007). The World Health Organization 
(WHO) estimates that about 19 million Nigerians have HBV infection, of which about 20% are chronic carriers 
and 40% of HBV carriers are likely to die from liver cancer or cirrhosis (Chiejina 2013).  
Studies undertaken in Nigeria have corroborated this figure. Indigenous research has shown that close to 20 
million Nigerians are infected with Hepatitis B with North Central and North East having the highest prevalence 
(Obom-Egbulem 2011). Although pregnant women are considered to have a lower risk of Hepatitis B virus 
infection, rates as high as 11% have been reported among them in Makurdi, North Central region of Nigeria 
(Yakubu et al. 1998; Mustapha et al. 2004). Similarly, blood donors who have previously been considered fairly 
healthy persons had prevalence as high as 14.3% (Uneke et al. 2005). Another study showed a total prevalence 
rate of 8.3% of HBsAg in Ebonyi State located in the South Eastern region of Nigeria. Similar prevalence figures 
emerged in studies carried out in Zaria (Luka et al. 2008) and Nnewi (Eke et al. 2011), indicating that the disease 
was fairly widespread geographically (Musa et al. 2015). The implications are that chronic HBV infection and 
the resulting liver diseases could pose a heavy burden for the Nigerian healthcare system 
Although there are small variations, it is clear that prevalence figures of between 10% and 30% in various 
relevant populations have emerged. These results call for concern as according to WHO’s (2009) classification 
for Hepatitis B virus endemicity, areas with 8.0% prevalence and above are considered endemic. The rising 
prevalence of HBV therefore presents a peculiar challenge for all relevant stakeholders due to the significant cost 
implications and the resultant effects on access to care. It has also been identified that viral hepatitis places a 
heavy burden on the health care system because of the high costs of treatment of liver cancer and failure from 
cirrhosis (WHO 2000).  
A review of the literature indicates that a comprehensive analysis of the financial burden of HBV infection in 
Nigeria is limited. In view of this, a cost of illness study of HBV infection was conducted prospectively based on 
treatment of recruited patients following a screening exercise. This evaluation was designed to examine the 
clinical outcomes of using PEG-IFNalfa- 2a and ET in order to determine the clinical outcomes and economic 
burden. The policy implications of the aforementioned are also explored. 
 
2. Methods 
Following ethics and governance approvals from the National Assembly (NASS) management, a prospective 
data collection approach was used to collect information from 100 randomly selected patients attending the 
NASS Medical Centre. The patients who tested positive for HB ‘e’ surface antigen were recruited for treatment 
and monitored as out-patients while data collection was carried out during patients’ visits. Relevant data were 
collected through interviews as well as retrieval from the medical records unit of the NASS Medical Centre. The 
study was carried out between January 2012 and December 2014. Patients were monitored and investigated at 
intervals on the basis of clinical manifestations; viral load (VL) and liver function test (LFT), 
PEG–INFalfa-2a 180 mcg was administered weekly to the eight selected Patients for 48 weeks. A switch to 
Emtricitabine + Tenoforvir (ET) capsules once daily for 24 weeks was done for 3 patients who exhibited poor 
response to PEG–INFalfa-2a. Thereafter, PEG-INFalfa-2a was administered for another 36 weeks. The unit cost 
of the drugs was noted.  Similarly, the unit cost of laboratory investigations or procedures, clinic visits and other 
important factors, were noted. Total cost was subsequently determined. The direct medical cost estimated in the 
treatment of HBV infection included clinic visits (outpatient visits), investigations (laboratory tests and 
procedures), and drug cost. The study assessed resource utilization based on average private charges in 2012 
expressed in Naira and US Dollars (N170:$1). The use of proxy charges for the estimation of costs was adopted 
(Drummond et al. 2003) as health care in Nigeria is majorly funded by out of pocket payments (OOP). 
3. Results 
Figure 1 is a pie chart showing the percentage of HBV positive individuals in the screened population. Treatment 
of results in figure 2 indicates the patients profile after the 1st phase of treatment with PEG-INFalfa-2a. 
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Figure 1: Prevalence of HBV in Screened population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: First phase of treatment with PEG-INFalfa-2a and viral load profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T0 = 1st phase treatment with PEG-INFalfa-2a in 8 patients for 48 weeks. 
T48a = Viral load i.e. undetectable at T48 (62.5% of the patients) – 5 patients 
T48b = Viral load rose above 35 million copies/ml after T48 (37.5% of the patients) – 3 patients 
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Fig 3: Changes in viral load with time (weeks) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Direct Medical and Non-medical Costs 
A Therapies 
Phase 1 
PEG-IFN-2α,  8 Patients / 48 weeks N17,280,000 ($101,647)  
 
Phase 2 
ET, 3 Patients / 24 weeks         N1, 485,000 ($8,735.29) 
PEG-IFN-2α, 3 Patients/ 36 weeks:    N4, 860,000 ($28,588.24) 
 
B Laboratory Investigations 
Case detection 
HBsAg test/confirmation 8 Patients (P)     N20, 000 ($117.65) 
Viral load (copies/ml) 
T0, T24, T48; 8P            N1,200, 000 ($7,058.82) 
T72 T96x 3P     N 300,000 ($1,764.71) 
Liver Function Tests 
T0 T24 T48 X 8                     N120, 000 ($705.88) 
T72 T96X 3      N30, 000 ($176.47) 
 
Average Medical Expenditures per Patient 
Phase 1 (5P)  N2, 327,500 ($13, 691.18) 
Phase 1+2 (3P)  N4, 057,500 ($23,867.65) 
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C Direct Non-Medical Cost 
Phase 1 
Transportation8 P x (440 visits) at 750/trip       N330,000 ($1,941.17) 
Feeding 3P x 48 weeks (440 visits) @500/meal  N220,000 ($1,294.12) 
Total           N550, 000($3,235.29) 
 
Phase 2 
Transportation  3P (141) @ 750/trip  N105,750 ($622.06) 
Feeding 3P (141) @500/meal                N70,500 ($414.71) 
Total       N171, 250 ($1,007.35) 
 
Average Non- medical expenditures per Patient 
Phase 1 (5P)     N67,750 ($398.52) 
Phase 2      N57,083 ($335.78) 
Phase 1+2 (3P)     N124,833 ($734.31) 
 
Table 2: Summary of Direct Medical and Non-medical Expenditure per patient per batch 
 
             
Expenditure 
 Cost N ($) 
Batch A  Batch B 
 
Medical 
Phase 1 2,327,500 ($13,691.18) 2,327,500 ($13,691.18) 
Phase 2 -------- 1,730,000 ($10,176.47) 
Non–medical Phase 1 67,750 ($398.53) 67,750 ($398.53) 
Phase 2 -------- 57,083 ($335.78) 
Total 2,395,250 ($14,089.71) 4,182,333 ($24,601.96) 
 
4. Discussion 
This study aimed at evaluating HBV prevalence and treatment together with the cost implications associated 
with the disease.  It emerged that the prevalence for HbsAg in the sample was 7.2% (See Figure 1). Although at 
the lower end of the spectrum, this finding reflects the results of earlier studies in Nigeria that reported 
prevalence rate of 7 - 30% (Yakubu et al. 1998; Mustapha et al. 2004). The VL and the LFT showed high level of 
derangement as evidenced in Figure 3. These scenarios necessitated commencement of treatment. The first phase 
of treatment involved the use of only PEG-INFalfa-2a for duration of 48 weeks.  
The European Association for the Study of Liver (EASL 2009) recommends a HBV DNA level of 2000 
copies/mL as threshold for initiating therapy. This recommendation applies to patients who are either positive or 
negative for Hepatitis B e surface antigen (HBeAg) (EASL 2009).The protocol of initial therapy with PEG-
IFNalfa-2a in this study was based on the raised DNA VL above the threshold (VL at T0 : 88,100 - 16,850,702 
copies/ml) with abnormal Liver Enzymes Level. PEG-IFNalfa-2a monotherapy was used as first line treatment 
based on findings that the use of PEG-INFalfa-2a seems to result in the highest rate of off-treatment-sustained-
response after a one-year course of therapy (Brunetto et al. 2009). In contrast treatment with nucleoside analogue 
required a prolonged period for several years before HBsAg loss is observed (Janssen 2009). PEG-IFNalfa-2a 
works by a two-pronged approach; it stimulates the immune system as well as inhibits virus replication. In a 
study of a 48-week regimen, after 24 weeks of follow-up the HBeAg sero-conversion rate with PEG-IFNalfa-2a 
monotherapy was 32%, compared with 27% in those receiving combination therapy with Lamivudine (2′,3′-
dideoxy-3′-thiacytidine, commonly called 3TC), and 19% in those receiving 3TC monotherapy (Lau 2005). 
Additionally, PEG-IFNalfa-2a being a pro-drug with indirect antiviral activity confers a line of least tendency for 
development of drug resistance (Kukka 2014). 
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After 48 weeks of treatment with PEG-IFNalfa-2a, there was sero-conversion in 62.5% of the patients. Earlier 
studies have reported sero-conversion rate of 32% and above following the use of PEG-IFNalfa-2a (Flink et al. 
2006; Tangkijvanich et al. 2010). Although this study was not designed primarily to determine the sero-
conversion rate using different options, it nevertheless agrees with the choice of interferon as rational first line 
treatment for HBV patients based on clinical outcomes. Ours is a preliminary study that has revealed a sero-
conversion of 5 out of the 8 patients treated. This has given us an impetus for designing further studies of a 
broader population in order to establish statistical significance. The remaining 37.5% (3 Patients) were 
subsequently placed on ET. The latter group had therapy switch because there was significant increase in their 
VL from a minimum of 12,716,256 at T0 to a maximum of 35,348,000 at T48 and their ALT (alanine 
aminotransferase) level was more than twice the normal level in the range of 94-197 IU/mL. After a period of 24 
weeks treatment with ET, there was a significant drop in the HBV DNA to a range of 2,527- 3,000copies/mL. 
The ALT also dropped significantly to a normal range of 19 -30 IU/mL. The patients were then placed on PEG-
IFNalfa-2a resulting in a drop in their VL to levels not exceeding 2500 copies/ml after 96 weeks of cumulative 
treatment. 
The direct cost noted in the management of the HBV infection was quite revealing. The total medical cost for the 
8 patients (Batch A) summed up to $14,089.71. The direct medical cost amounted to 97.2% of the total burden 
while the direct non-medical cost was $398.53, corresponding to 2.8%. 
Previous studies have shown an alarmingly high HBV prevalence among various groups in the Nigerian setting 
(Ezegbudo et al. 2004; Fakunle et al. 1981; Ukaeje et al. 2005; Yakubu et al. 1998; Abiodun et al. 1986). Recent 
statistics indicate that not less than 23 million Nigerians are estimated to be infected with the HBV making 
Nigeria one of the countries with the highest incidence of HBV infection in the world (Ottet al. 2012). The 
average prevalence of Hepatitis B virus infection in Nigeria is about 13 per cent, with higher prevalence in rural 
areas than urban areas. HBV is more common and more contagious than HIV, which has an average prevalence 
rate of 4.5% (Mbaawuaga 2014). The foregoing indicates that attention must be focused on curtailing the spread 
of HBV in the country. 
OOP remains an important source of funding for healthcare in the country, accounting for more than 90% of 
private expenditures on health. The cost of treatment for HBV infection may be significant for the average 
Nigerian patient as antiviral drugs and adjunct treatment remain expensive. In assessing poverty, the Nigerian 
Bureau of Statistics uses several indices including absolute measure; the dollar per day measure; and the 
subjective poverty measure. The absolute measure puts the country’s poverty rate at 99.284 million or 60.9 per 
cent; the dollar per day measure puts the rate at 61.2 per cent; and the subjective poverty measure puts it at 93.9 
per cent (Nigerian Insight 2014). Our study population comprised of low to middle income earners whose annual 
income is estimated to be N660,000 ($3,882.35). This figure represents 24% of the estimated total medical 
cost/patient. What this means is that the income of a middle income earner is inadequate to treat the disease 
effectively.  
The World Health Organization (WHO) estimates that households that spend 40% or more of their non-food 
expenditure on treatment are most likely to be impoverished (Leighton 1993). Some researchers argue that a cost 
burden greater than 10% is likely to be catastrophic for the household economy (Prescott 1999; Ranson 2002). 
Even with health insurance coverage, the direct costs of HBV-related diseases, except acute Hepatitis B, 
exceeded 40% of household annual income in China, suggesting that HBV-related diseases should be  
categorized as catastrophic (Ku et al. 2003; Kawabata et al. 2002). This means that in Nigeria, it is likely to force 
household members to cut their consumption of other basic needs. It could also lead to high levels of debt and 
impoverishment since payment for health services by the majority of the population is largely OOP. Alternatively, 
the financial burden may cause patients to refrain from seeking care in an attempt to save cost. The consequences 
will include increased spread of HBV; individual and national productivity loss; and even higher mortality rate 
due to complications.   
From the evidence, it is clear that Hepatitis B presents a significant challenge for national healthcare in Nigeria. 
Current treatment protocols and costs impact heavily on the economy, both at an individual, and at a national 
level. Also, national preventive measures are absent, or at best, uncoordinated. Unfortunately, not much attention 
has been given to the control of Hepatitis B globally, including in Nigeria where this burden is rapidly increasing. 
It is unclear what, if any strategies exist for addressing what appears to be a fast approaching National Health 
Emergency. It is against this backdrop that we argue for the development of a comprehensive strategy to 
underpin the prevention and treatment of Hepatitis B.  
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5. Conclusion 
Findings from this study have confirmed that PEG-INFalfa-2a is suitable for treatment of Hepatitis B infections 
in Nigeria. The cost of treatment is however a significant limitation. Stakeholders including pharmaceutical 
manufacturers, health insurance providers and other healthcare organisations and professionals are enjoined to 
work out efficient and effective means of making the cost of PEG-INFalfa-2a more affordable. The cost 
implication in the combined use of PEG-INFalfa-2a and ET occasioned by therapy switch is unacceptably high 
despite the good clinical outcomes. Further studies can also undertake an exploration of the cost benefit analysis 
of this combination in contrast to pairs of PEG INFalfa-2a and other ARTs similar to ET.  
Insufficient local funding and inadequate awareness for Hepatitis B virus infection are fuelling the disease spread. 
This has led to millions of Nigerians developing liver cancer/cirrhosis with consequent high medical 
expenditures and loss of human capital. Improved health insurance coverage with expanded benefit package can 
help reduce the financial burden of the disease on the most vulnerable sections of the populace. Better 
engagement and advocacy by national and international development agencies and organisations, can improve 
funding as well as increase awareness Additionally, prevention of the disease through efficient public education 
and the use of vaccines may significantly scale down the prevalence of the infection. It is therefore our opinion 
that HBV infection be considered a public health issue. This will form the basis for the development of 
comprehensive and robust policies to help prevent the spread of HBV as well as provide affordable treatment for 
infected individuals. 
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